Payer coverage policies for multigene tests

Kathryn A Phillips^{1

2

3}, Patricia A Deverka^{4

5}, Julia R Trosman^{1

6

7}, Michael P Douglas¹, James D Chambers^{8

9}, Christine B Weldon^{6

7}, Andrew P Dervan¹⁰

Affiliations

¹ Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco, California, USA.
² Philip R. Lee Institute for Health Policy, University of California San Francisco, San Francisco, California, USA.
³ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
⁴ American Institutes for Research, Chapel Hill, North Carolina, USA.
⁵ University of North Carolina, Eshelman School of Pharmacy, Center for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina, USA.
⁶ Center for Business Models in Healthcare, Chicago, Illinois, USA.
⁷ Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁸ The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies.
⁹ Tufts Medical Center, Boston, Massachusetts, USA.
¹⁰ Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA.

Kathryn A Phillips et al. Nat Biotechnol. 2017.

. 2017 Jul 12;35(7):614-617.

doi: 10.1038/nbt.3912.

Kathryn A Phillips^{1

2

3}, Patricia A Deverka^{4

5}, Julia R Trosman^{1

6

7}, Michael P Douglas¹, James D Chambers^{8

9}, Christine B Weldon^{6

7}, Andrew P Dervan¹⁰

¹ Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco, California, USA.
² Philip R. Lee Institute for Health Policy, University of California San Francisco, San Francisco, California, USA.
³ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
⁴ American Institutes for Research, Chapel Hill, North Carolina, USA.
⁵ University of North Carolina, Eshelman School of Pharmacy, Center for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina, USA.
⁶ Center for Business Models in Healthcare, Chicago, Illinois, USA.
⁷ Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁸ The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies.
⁹ Tufts Medical Center, Boston, Massachusetts, USA.
¹⁰ Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA.

No abstract available

Conflict of interest statement

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

1. Kolata G, Harris G. New York Times. 2016 Jan 13;:A17.
1. Phillips KA. J Am Med Assoc. 2008;300:2542–2544. - PubMed
1. Hresko A, Haga SB. J Pers Med. 2012;2:201–216. - PMC - PubMed
1. Graf M, Needham D, Teed N, Brown T. Per Med. 2013;10:235–243. - PubMed
1. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Nat Biotechnol. 2015;33:900–902. - PMC - PubMed